Introduction {#Sec1}
============

Skin and skin structure infections (SSSIs) are among the most common bacterial infections in patients presenting in emergency rooms and their incidence is rising \[[@CR1]--[@CR3]\]. In 1998, FDA classified SSSI as complicated (cSSSI) if it involves deep subcutaneous tissues or requires surgery \[[@CR4]\]. Although initially designed for the clinical trials, the umbrella term cSSSI is still useful in the detection of the most severe forms of SSSIs \[[@CR5]\].

Blood cultures are not routinely recommended for patients with SSSI \[[@CR6], [@CR7]\]. This is mainly because positive findings have been rare \[[@CR8]\] and have only seldom affected antibiotic treatment \[[@CR9]\]. However, this might not be generalizable to all SSSIs since the rate of bacteremia has been reported to increase in more severe cases. Whereas blood culture positivity of 4.6% has been reported in erysipelas, it was 7.9% in cellulitis \[[@CR10]\] and even higher rate of 11.9% was reported in a recent European survey on cSSSI \[[@CR11]\]. Factors associated with bacteremia in cSSSI have not been studied, but in less severe SSSI comorbidity \[[@CR12]\] in another study, up to 11 patient factors, including male gender and older age, were linked to bacteremia \[[@CR13]\].

We conducted a population-based study including 460 patients with cSSSI from two Nordic cities and reported that at least 13.3% of patients had a bloodstream infection with equal yield of one fourth of samples being positive in both study sites \[[@CR14]\]. Male gender and cellulitis were associated with blood culture sampling and bacteremia with later clinical stability \[[@CR14], [@CR15]\]. In the present study, we analysed further from the same real-life setup factors predicting and associated with blood culture positivity and how the knowledge of blood culture positivity affected the treatment.

Materials and methods {#Sec2}
=====================

The study design was a retrospective observational cohort study. All adult patients hospitalised for cSSSI within a 4-year period 2008--2011 in Helsinki University Hospital and Helsinki City Hospital in Helsinki, Finland (604,000 inhabitants), and Sahlgrenska University Hospital in Gothenburg, Sweden (525,000 inhabitants), were included in the study \[[@CR14]\]. Patients were recognised using *International Classification of Diseases* (ICD-10) codes and demographic and clinical data were collected from the medical records. These hospitals have the only emergency departments in their catchment areas why virtually all hospitalised patients with cSSSI have been included enabling the population-based approach. The prevalence of methicillin-resistant *Staphylococcus aureus* was 2.8% in Finland \[[@CR16]\] and 0.8% in Sweden in 2011 \[[@CR17]\].

Detailed study protocol is presented in the primary publication of this study \[[@CR14]\]. In short, to be included, patients were required to have infection affecting deeper soft tissue (e.g. cellulitis or fasciitis), infection requiring significant surgical intervention, infection which developed on a lower extremity in a patient with diabetes mellitus or peripheral vascular disease or to have a major abscess or an infected ulcer. Patients also had to have at least one systemic sign of infection: temperature \> 38 °C or \< 36 °C or white blood cell count \> 10,000/mm^3^ or \< 4000/mm^3^.

Study definitions and statistical analyses {#Sec3}
------------------------------------------

Microbial diagnosis was obtained by blood culture, bacterial culture of tissue or superficial swabs in routine cultures. Cellulitis/fasciitis was defined as an infection without abscess, diabetic foot/leg ulcer or peripheral vascular disease ulcer. The evaluation of clinical stability was based on improvement of vital signs and decrease of fever. Streamlining was defined as change of antibiotic therapy to pathogen specific one. Microbes from normal cutaneous flora (e.g. coagulase-negative staphylococci) were generally not considered as pathogens in blood cultures and an infectious disease specialist assessed each case. Antibiotic treatment prescribed before admission or before the fulfilment of cSSSI criteria during the hospitalisation was recorded.

Categorical variables were summarised using counts and percentages. Continuous variables were summarised using means and standard deviation (SD) or median, interquartile range (IQR), or range if subgroup was small. In univariate analysis, the difference between two groups was compared using chi-square test or Fisher's exact test, as appropriate. Continuous variables were analysed using a two-sample *t* test or Mann-Whitney *U* test if variables were not normally distributed. Odds ratio (OR) was calculated with 95% confidence interval (CI). Multivariate logistic regression was performed including variables that were clinically relevant, had univariate *p* values less than 0.15 and were not multicollinear. *P* value \< 0.05 was considered significant. SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses.

Factors associated with blood culture sampling were analysed also using multivariate logistic regression analysis and factors associated with bacteremia were analysed by comparing blood culture positive patients with blood culture negative patients. This approach differs from the analysis performed in the previous publications of this material \[[@CR14], [@CR15]\].

Results {#Sec4}
=======

Blood culture findings {#Sec5}
----------------------

In total, 460 patients with cSSSI were included. Blood cultures were drawn from 258 (51.6%) patients and they were positive in 61 (23.6%). Although there was some heterogeneity in the patient populations between the two centres \[[@CR18]\], proportion of positive blood cultures was almost equal, in Helsinki 22.9% and 25% in Gothenburg. Blood culture isolates were *Streptococcus pyogenes* 19 cases (31.1%), *Staphylococcus aureus* 19 (31.1%), non-A beta-hemolytic streptococci 12 (19.7%), *Streptococcus pneumoniae* 1 (1.6%), *Enterobacteriaceae* spp. 1 (1.6%), polymicrobial 5 (8.2%) and unknown (4/6.6%).

Factors associated with blood culture sampling {#Sec6}
----------------------------------------------

Patients from whom blood cultures were drawn (*n* = 258) were compared to those from whom blood cultures were not drawn (*n* = 202) for this analysis (Table [1](#Tab1){ref-type="table"}).Table 1Demographics, clinical features and laboratory findings of 460 patients with cSSSI according to if blood culture sample was taken or not taken. Data is shown as number of patients (%) in each columnVariableAll (*n* = 460)Blood cultures drawn (*n* = 258)Blood cultures not drawn (*n* = 202)OR (95% CI)*P* valueMultivariate logistic regression analysisOR (95% CI)*P* valueMale gender280 (60.9)168 (65.1)112 (55.4)1.5 (1.0--2.2)0.0351.2 (0.8--1.9)0.337Age, years \[mean (SD)\]67.4 (18.1)66.8 (17.5)68.1 (19.0)0.465Diabetes187 (40.7)120 (46.5)67 (33.2)1.7 (1.2--2.6)0.0041.9 (1.2--2.9)0.008Peripheral vascular disease135 (29.3)62 (24.0)73 (36.1)0.6 (0.4--0.8)0.0050.5 (0.3--0.8)0.007Congestive heart disease43 (9.3)23 (8.9)20 (9.9)0.9 (0.5--1.7)0.718Respiratory disease34 (7.4)22 (8.5)12 (5.9)1.5 (0.7--3.1)0.293Chronic renal disease32 (7.0)21 (8.1)11 (5.4)1.5 (0.7--3.3)0.260Liver disease23 (5.0)14 (5.4)9 (4.5)1.2 (0.5--2.9)0.673HIV infection7 (1.5)5 (1.9)2 (1.0)2.0 (0.4--10.3)0.474Any disease with immune system impairment14 (3.0)6 (2.3)8 (4.0)0.6 (0.2--1.7)0.311Malignancy36 (7.8)19 (7.4)17 (8.4)0.9 (0.4--1.7)0.677Alcohol abuse40 (8.7)28 (10.9)12 (5.9)1.9 (1.0--3.9)0.0641.4 (0.6--3.1)0.475Intravenous drug use32 (7.0)15 (5.8)17 (8.4)0.7 (0.3--1.4)0.276No. of co-morbidities ≥ 2171 (37.2)98 (38.0)73 (36.1)1.1 (0.7--1.6)0.684Hospitalisation \< 3 months84 (18.3)44 (17.1)40 (19.8)0.8 (0.5--1.3)0.449Invasive surgery \< 3 months71 (15.4)33 (12.8)38 (18.8)0.6 (0.4--1.1)0.076Antibiotic treatment before dg128 (27.8)58 (22.5)70 (34.7)0.5 (0.4--0.8)0.0040.7 (0.4--1.1)0.115Abscess183 (39.8)91 (35.3)92 (45.5)0.7 (0.4--1.0)0.025Cellulitis/fasciitis (no abscess or ulcer)193 (42.0)128 (49.6)65 (32.2)2.1 (1.4--3.0)\< 0.0011.6 (1.0--2.5)0.052Decubitus or pressure ulcer14 (3.0)6 (2.3)8 (4.0)0.6 (0.2--1.7)0.311Diabetic foot/leg ulcer66 (14.3)31 (12.0)35 (17.3)0.7 (0.4--1.1)0.107Peripheral vascular disease ulcer53 (11.5)21 (8.1)32 (15.8)0.5 (0.3--0.8)0.010Post-surgical wound79 (17.2)35 (13.6)44 (21.8)0.6 (0.3--0.9)0.0200.4 (0.2--0.8)0.005Post-traumatic wound50 (10.9)30 (11.6)20 (9.9)1.2 (0.7--2.2)0.555Anatomical site of the infection  Head5 (1.1)4 (1.6)1 (0.5)3.2 (0.4--28.5)0.391  Hand9 (2.0)4 (1.6)5 (2.5)0.6 (0.2--2.3)0.515  Trunk142 (30.9)73 (28.3)69 (34.2)0.8 (0.5--1.1)0.177  Upper extremities52 (11.3)33 (12.8)19 (9.4)1.4 (0.8--2.6)0.255  Lower extremities284 (61.7)167 (64.7)117 (57.9)1.3 (0.9--1.9)0.1361.4 (0.8--2.2)0.214Duration of symptoms before the diagnosis  \< 2 days130 (28.3)97 (37.6)33 (16.3)3.1 (2.0--4.8)\< 0.0013.0 (1.8--5.2) ^1^\< 0.001  2--7 days230 (50.0)129 (50)101 (50.0)1.0 (0.7--1.4)\> 0.99  \> 7 days90 (19.6)29 (11.2)61 (30.2)0.3 (0.2--0.5)\< 0.001C-reactive protein (CRP) mg/L (*n* = 425)  1st day CRP \> 150214 (50.4)139 (57.0)75 (41.4)1.9 (1.3--2.8)0.0021.8 (1.2--2.8)0.006  1st day CRP \[median (IQR)\]157 (81--252)181 (91--266)130 (73--210)0.003*OR* odds ratio, *CI* confidence interval, *HIV* human immunodeficiency virus, *No.* number, *Dg* diagnosis, *IQR* interquartile range^1^In multivariate logistic regression analysis, this variable is included as dichotomic (i.e. symptoms shorter than 2 days compared to longer than 2 days)

In logistic regression analysis, diabetes (OR 1.9, *P* = 0.008), peripheral vascular disease (OR 0.5, *P* = 0.007), post-surgical wound infection (OR 0.4, *P* = 0.005), symptoms shorter than 2 days (OR 3.0, *P* \< 0.001) and CRP over 150 mg/L on the first day (OR 1.8, *P* = 0.006) were significantly associated with blood culture sampling (Table [1](#Tab1){ref-type="table"}).

Factors associated with blood culture positivity {#Sec7}
------------------------------------------------

To analyse factors associated with blood culture positivity, we compared patients with a positive blood culture (*n* = 61) to patients with a negative blood culture (*n* = 197).

Results of comparisons between the groups are shown in Table [2](#Tab2){ref-type="table"}. Neither CRP measured at the time of the diagnosis of cSSSI nor the highest CRP during the hospital stay was associated with blood culture positivity (Table [2](#Tab2){ref-type="table"}). In multivariate logistic regression analysis, only factor associated significantly with bacteremia was alcohol abuse (OR 5.5, *P* \< 0.001).Table 2Difference in demographics and clinical features of patients with blood culture positivity and negativity among 258 patients with cSSSI and blood culture sample taken. Data is shown as number of patients (%) in each columnVariableAll (*n* = 258)Positive blood cultures (*n* = 61)Negative blood cultures (*n* = 197)OR (95% CI)*P* valueMultivariate logistic regression analysisOR (95% CI)*P* valueDemographics and co-morbidities  Male gender168 (65.1)42 (68.9)126 (64.0)1.2 (0.7--2.3)0.484  Age \> 60 years165 (64.0)40 (65.6)125 (63.5)1.1 (0.6--2.0)0.763  Age, years \[mean (SD)\]66.8 (17.5)66.2 (16.4)67.0 (17.9)0.734  Diabetes120 (46.5)27 (44.3)93 (47.2)0.9 (0.5--1.6)0.687  Peripheral vascular disease62 (24.0)15 (24.6)47 (23.9)1.0 (0.5--2.0)0.907  Congestive heart disease23 (8.9)2 (3.3)21 (10.7)0.3 (0.1--1.2)0.0770.2 (0.05--1.04)0.057  Respiratory disease22 (8.5)9 (14.8)13 (6.6)2.5 (1.0--6.0)0.0462.2 (0.8--5.8)0.133  Chronic renal disease21 (8.1)3 (4.9)18 (9.1)0.5 (0.1--1.8)0.423  Liver disease14 (5.4)6 (9.8)8 (4.1)2.6 (0.9--7.7)0.104  HIV infection5 (1.9)1 (1.6)4 (2.0)0.8 (0.1--7.3)\> 0.999  Any disease with immune system impairment6 (2.3)3 (4.9)3 (1.5)3.3 (0.7--17.0)0.146  Cancer/malignancy19 (7.4)5 (8.2)14 (7.1)1.2 (0.4--3.4)0.781  Alcohol abuse28 (10.9)15 (24.6)13 (6.6)4.6 (2.1--10.4)\< 0.0015.5 (2.3--13.2)\< 0.001  Intravenous drug use15 (5.8)3 (4.9)12 (6.1)0.8 (0.2--2.9)\> 0.999  No. of co-morbidities ≥ 298 (38.0)26 (42.6)72 (36.5)1.3 (0.7--2.3)0.393  Hospitalisation \< 3 months44 (17.1)12 (19.7)32 (16.2)1.3 (0.6--2.6)0.534  Invasive surgery \< 3 months33 (12.8)7 (11.5)26 (13.2)0.9 (0.4--2.1)0.725  Antibiotic treatment before dg58 (22.5)14 (23)44 (22.3)1.0 (0.5--2.0)0.920Clinical features  Abscess91 (35.3)15 (24.6)76 (38.6)0.5 (0.3--1.0)0.046  Cellulitis/fasciitis128 (49.6)37 (60.7)91 (46.2)1.8 (1.0--3.2)0.0481.6 (0.8--3.2)0.162  Decubitus or pressure ulcer6 (2.3)1 (1.6)5 (2.5)0.6 (0.1--5.6)\> 0.999  Diabetic foot/leg ulcer31 (12.0)9 (14.8)22 (11.2)1.4 (0.6--3.2)0.452  Peripheral vascular disease ulcer21 (8.1)3 (4.9)18 (9.1)0.5 (0.1--1.8)0.423  Post-surgical wound35 (13.6)5 (8.2)30 (15.2)0.5 (0.2--1.3)0.161  Post-traumatic wound30 (11.6)10 (16.4)20 (10.2)1.7 (0.8--3.9)0.184Anatomical site of the infection  Head4 (1.6)2 (3.3)2 (1.0)3.3 (0.5--24.0)0.238  Hand4 (1.6)1 (1.6)3 (1.5)1.000\> 0.999  Trunk73 (28.3)10 (16.4)63 (32.0)0.4 (0.2--0.9)0.018  Upper extremities33 (12.8)12 (19.7)21 (10.7)2.1 (0.9--4.5)0.066  Lower extremities167 (64.7)45 (73.8)122 (61.9)1.7 (0.9--3.3)0.0912.0 (0.98--4.2)0.055Duration of symptoms before the diagnosis  \< 2 days97 (37.6)28 (45.9)69 (35.0)1.6 (0.9--2.8)0.1251.3 (0.7--2.6)^1^0.425  2--7 days129 (50)21 (34.4)108 (54.8)0.4 (0.2--0.8)0.005  **\>** 7 days29 (11.2)11 (18.0)18 (9.1)2.2 (1.0-4.9)0.055 C-reactive protein (CRP) mg/L  1st day CRP count \[median (IQR)\] (*n* = 244)181 (91--266)201 (97--286)170 (89--261)0.410  Highest CRP count \[median (IQR)\] (*n* = 256)240 (156--320)243 (166--331)240 (150--311)0.465*OR* odds ratio, *CI* confidence interval, *SD* standard deviation, *No.* number, *Dg* diagnosis, *CRP* C-reactive protein, *IQR* interquartile range^1^In multivariate logistic regression analysis, this variable is included as dichotomic (i.e. symptoms shorter than 2 days compared to longer than 2 days)

Clinical endpoints in blood culture positivity {#Sec8}
----------------------------------------------

Bacteremic patients (*n* = 61) were less likely to reach clinical stability within 3 days and they were more often admitted to intensive care unit and had significantly longer hospital stay than blood culture negative patients (Table [3](#Tab3){ref-type="table"}). In addition, 23.3% of blood culture positive patients had antibiotic treatment streamlined as compared to 6.3% of culture negative patients (*P* = 0.0002).Table 3Outcome of 258 cSSSI patients from whom blood cultures were drawn. Data is shown as number of patients (%) in each columnVariableAll (*n* = 258)Positive blood cultures (*n* = 61)Negative blood cultures (*n* = 197)Odds ratio (95% CI)*P* valueClinical stability within 3 days (*n* = 223)105 (47.1)15 (30)90 (52)0.4 (0.2--0.8)0.006Admission to ICU51 (19.8)20 (32.8)31 (15.7)2.6 (1.4--5.0)0.003Surgical intervention after the diagnosis of cSSSI129 (50)34 (55.7)95 (48.2)1.4 (0.8--2.4)0.30530-day mortality16 (6.2)4 (6.6)12 (6.1)1.1 (0.3--3.5)\> 0.999Streamlining (*n* = 251)26 (10.4)14 (23.3)12 (6.3)4.5 (2.0--10.5)\< 0.001Duration of antimicrobial treatment, days \[median (IQR)\] (*n* = 255)21 (12--38)26 (11.5--46.8)20 (12--38)0.191Length of hospital stay, days \[median (IQR)\] (*n* = 228)15 (8--29)19.5 (13--45.3)13 (7--23)\< 0.001*CI* confidence interval, *IQR* interquartile range

Discussion {#Sec9}
==========

In this population-based study, we observed that 23.6% of the cSSSI patients from whom blood culture was taken had bacteremia. Streptococci and *Staphylococcus aureus* corresponded for 84% of cases. Bacteremia was associated with later clinical stability, more ICU admissions and more common streamlining. Higher CRP was linked to more common blood culture sampling, but not to culture positivity. Diabetes and duration of symptoms shorter than 2 days were observed to increase the likelihood of blood culture sampling, but only alcoholism increased the likelihood of blood culture positivity.

Blood culture positivity reported here was higher than 11.6% in a multi-centre study from Central and Southern Europe, which had a sampling rate of 53% \[[@CR11]\]. The most evident explanation is that our patient material was more severe. Blood culture positivity rate in less severe SSSIs like erysipelas or cellulitis has been reported to be 4.6--9% \[[@CR10], [@CR19]\].

In previous study on this patient material, it was observed that patients who had blood cultures drawn had higher mortality suggesting that clinicians ordered blood cultures from sicker patients \[[@CR14]\]. Although the blood culture drawing rate differed in the two centres, the rate of positive findings was equal suggesting that blood cultures should most probably be taken with lower threshold in cSSSI.

Diabetes and higher CRP provoked clinicians to order blood culture sampling in accordance with data in erysipelas \[[@CR19]\] and uncomplicated cellulitis \[[@CR20]\]. In contrast to one previous study, prior antibiotic treatment was not negatively associated with positive blood culture findings but it resulted in less common (45.3%) sampling than compared to patients without prior antibiotics (54.7%, *P* = 0.004) \[[@CR21]\]. Alcohol abuse had a striking association with blood culture positivity, as of patients with a history of alcohol abuse 53.6% had bacteremia as compared to 20% of those who did not. Similarly, in patients with uncomplicated cellulitis, alcohol abuse was the only discriminant patient characteristic associated with bacteremia \[[@CR20]\].

Beta-hemolytic streptococci and *Staphylococcus aureus* were not only the most common blood culture findings but they also constituted 64% of all cSSSI cases in which the aetiology was verified. Whereas we observed only one case of gram-negative monobacteremia, Van Daalen et al. found more gram-negative bacteria than *Staphylococcus aureus* \[[@CR12]\] and Peralta et al. observed a gram-negative aetiology in 24.6% of bacteremias \[[@CR21]\]. Accordingly, in a systematic review of patients with cellulitis and erysipelas, gram-negative bacteria were concluded to be at least as common as *S. aureus* in blood cultures in cellulitis \[[@CR10]\]. These differences might be explained by difference in patient selection in these studies.

Our results contradict the view that blood cultures would not be useful because in complicated cellulitis they rarely had an effect on antibiotic therapy \[[@CR9]\]. In our material, antibiotic treatment was streamlined more often in bacteremic than in non-bacteremic patients (23.3% versus 6.3%, *P* \< 0.001). Accordingly, a change in the antibiotic treatment was recorded in 49% of patients with lower limb cellulitis after blood culture results became positive \[[@CR21]\]. Furthermore, in countries with higher antibiotic resistance, the importance of blood culture-directed therapy has been pointed out \[[@CR22]\].

Blood culture positivity was linked to later clinical stability, which without culture result might lead to a premature change of antibiotic treatment to more broad-spectrum. However, positive blood culture was not linked to longer antibiotic treatment or higher mortality as has been reported previously \[[@CR11]\]. The likely explanation to these differences is the low number of bacteremic patients and virtual lack of gram-negative and resistant bacteria in our study.

The strength of this study is its population-based nature, although some patients may have been unrecognised due to coding inaccuracy. Major limitations of this study are due to its retrospective nature. Data was collected from medical records, which left missing data in some parameters. Fifty-six percent of patients were subjected to blood culture sampling and were included in the analysis of factors associated with bacteremia, creating an inevitable selection bias.

In this population-based study in cSSSI, we observed that a positive blood culture was more common than previously reported and affected 23.6% of patients with blood culture sampled. Factors linked to higher blood culture sampling rate were not generally related to higher positive finding yield. A clear benefit of blood culture positivity on patient management was shown in more frequent antibiotic streamlining and knowledge of later clinical stability.
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